Masao Suzuki, L.Ac., Ph.D., of Kyoto Meiji and University University of Integrative Medicine, Kyoto, Japan, and co-workers conducted a randomized controlled trial from July 2006 through March 2009. A complete of 68 patients identified as having COPD participated, and 34 were designated to a genuine acupuncture group for 12 weeks, plus daily medicine. The additional 34 were assigned to a placebo acupuncture group where the needles were blunt . The principal measure was the evaluation of a six-minute walk check on a Borg scale where 0 meant inhaling and exhaling perfectly, barely breathless and 10 signified severely breathless.We anticipate the factor and conclusions of regulatory authorities now.’ Carlo Russo, M.D., Senior Vice President, Biopharm Advancement, GSK, stated, ‘With both of the pivotal Phase 3 trials completed effectively, the results presented at main scientific meetings and regulatory applications today under review, we very much hope that we can deliver a fresh option for the treatment of systemic lupus.’ Belimumab is an investigational medication and the initial in a fresh class of drugs called BLyS-specific inhibitors. It is being developed by HGS and GSK under a co-development and commercialization agreement entered into in 2006. GSK submitted a Marketing Authorization Program to the European Medications Agency on June 4, 2010, seeking acceptance to advertise belimumab in European countries for treatment of autoantibody-positive individuals with SLE.